Page
%P
-
Article
Open AccessSafety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2
We used the RNActive® technology platform (CureVac N.V., Tübingen, Germany) to prepare CVnCoV, a COVID-19 vaccine containing sequence-optimized mRNA coding for a stabilized form of SARS-CoV‑2 spike (S) protein...